Vivos Therapeutics, Inc.
VVOSNASDAQHealthcare● Active
$0.87
+$0.01(+0.64%)
Market Cap$5123882
P/E Ratio—
52W High$7.95
52W Low$0.545
Vivos Therapeutics, Inc. (VVOS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VVOS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $17.44M | $15.03M | $13.80M | $16.02M | $16.89M |
| Cost of Revenue | $6.90M | $6.01M | $5.53M | $6.00M | $4.28M |
| Gross Profit | $10.54M | $9.02M | $8.27M | $10.02M | $12.60M |
| Gross Margin %(computed) | 60.44% | 60.00% | 59.93% | 62.52% | 74.65% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $27.73M | $17.88M | $22.48M | $29.04M | $25.79M |
| Total Operating Expenses | $30.44M | $20.19M | $25.57M | $35.05M | $32.08M |
| Operating Income | ($19.89M) | ($11.17M) | ($17.30M) | ($25.03M) | ($19.47M) |
| Operating Margin %(computed) | -114.05% | -74.32% | -125.32% | -156.21% | -115.32% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.09M | $0.12M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.01M |
| Income Before Tax | ($21.23M) | ($11.14M) | ($13.58M) | ($23.84M) | ($20.29M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($21.23M) | ($11.14M) | ($13.58M) | ($23.84M) | ($20.29M) |
| Net Margin %(computed) | -121.71% | -74.09% | -98.42% | -148.81% | -120.15% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.06 | $-2.22 | $-11.14 | $-25.90 | $-23.89 |
| Wtd Avg Shares | 10.27M | 5.02M | 1.22M | 0.92M | 0.85M |
| EBITDA | ($18.59M) | ($10.59M) | ($16.68M) | ($24.36M) | ($19.54M) |
| EBITDA Margin %(computed) | -106.55% | -70.45% | -120.82% | -152.03% | -115.73% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Vivos Therapeutics, Inc. data
About Vivos Therapeutics, Inc. (VVOS) Income Statement
Vivos Therapeutics, Inc. (VVOS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VVOS reported revenue of $0.02B, gross profit of $0.01B (gross margin 60.44%), and net income of ($0.02B) — a net profit margin of -121.71%.
Frequently asked questions
VVOS · 4 questionsVivos Therapeutics, Inc. (VVOS) reported revenue of $0.02B for 2025, up 16.0% year-over-year.
VVOS revenueVVOS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08